New drugs and formulations for pancreatic cancer at ESMO WorldGI: NAPOLI-1 and MPACT trials

  • Date: 05 Aug 2014

Speaker: Eric Van Cutsem

E. van Cutsem comments two studies: NAPOLI-1, demonstrating improved survival for MET pancreatic cancer patients with the novel drug MM-398; the SPARC analysis of MPACT, showing that the protein cannot be used as predictive marker for gemcitabine + nab-paclitaxel. There is still an unmet need to identify Predictive markers for these patients.

Discussion Points

Top line results of NAPOLI-1 study:

  • What is nal-IRI? What are the mechanisms of action?
  • What are the important side-effects?

Searching biomarkers for the treatment of pancreatic cancer with nab-paclitaxel: The SPARC analysis in the phase III MPACT trial